Mutational profile of primary clear cell renal cell carcinoma predicts recurrence and potential candidacy for adjuvant immune checkpoint inhibition
F1000Research · 2024
DOI: 10.12688/f1000research.136087.2 ↗Kurz gefasst
Fachartikel in der Zeitschrift F1000Research, 2024. Verfasst von Panagiotis J Vlachostergios und 9 weiteren Autor:innen. Beteiligte Einrichtung: Urology, University of Thessaly, Faculty of Medicine, School of Health Sciences, University Hospital of Larissa, Larissa, Thessalia, Greece. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Mutation, Immune Checkpoint Inhibitors. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union and Greek national funds, Operational Program Competitiveness, Entrepreneurship and Innovation, under RESEARCH—CREATE—INNOVATE.
Abstract (Originalsprache)
Background
The risk of recurrence after nephrectomy for primary clear cell renal cell carcinoma (ccRCC) is estimated in daily practice solely based on clinical criteria. The aim of this study was to assess the prognostic relevance of common somatic mutations with respect to tumor aggressiveness and outcomes of ccRCC patients after definitive treatment.
Methods
Primary tumors from 37 patients with ccRCC who underwent radical nephrectomy were analyzed for presence of somatic mutations using a 15-gene targeted next-generation sequencing (NGS) panel. Associations to histopathologic characteristics and outcomes were investigated in the study cohort (n=37) and validated in The Cancer Genome Atlas (TCGA) ccRCC cohort (n=451).
Results
VHL was the most frequently mutated gene (51%), followed by PBRM1 (27%), BAP1 (13%), SETD2 (13%), KDM5C (5%), ATM (5%), MTOR (5%), and PTEN (3%). One-third of patients did not have any somatic mutations within the 15-gene panel. The vast majority of tumors harboring no mutations at all or VHL-only mutations (51%) were more frequently of smaller size (pT1-2) and earlier stage (I/II), whereas presence of any other gene mutations in various combinations with or without VHL was enriched in larger (pT3) and higher stage tumors (III) (p=0.02). No recurrences were noted in patients with unmutated tumors or VHL -only mutations as opposed to three relapses in patients with non- VHL somatic mutations (p=0.06). Presence of somatic mutations in PBRM1, BAP1, SETD2, KDM5C, ATM, MTOR , or PTEN genes in 451 TCGA ccRCC patients was associated with a significantly shorter disease-free survival (DFS) compared to those with unaltered tumors (q=0.01).
Conclusions
Preliminary findings from this ongoing study support the prognostic value of non- VHL mutations including PBRM1, BAP1, SETD2, KDM5C, ATM, MTOR , and PTEN in primary ccRCC tumors as surrogates of earlier recurrence and potential selection for adjuvant immune checkpoint inhibition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Urology, University of Thessaly, Faculty of Medicine, School of Health Sciences, University Hospital of Larissa, Larissa, Thessalia, Greece.
- Medical Oncology, IASO Thessalias Hospital, Larissa, Thessalia, Greece.
- Hematology & Medical Oncology, Weill Cornell Medicine, New York, New York, USA.
- Pathology, University of Thessaly, Faculty of Medicine, School of Health Sciences, Larissa, Greece.
- Computer Science and Biomedical Informatics, University of Thessaly, Lamia, Greece.
ORCID-Profile: Panagiotis J Vlachostergios, Ioannis Tamposis
Förderung
- European Union and Greek national funds, Operational Program Competitiveness, Entrepreneurship and Innovation, under RESEARCH—CREATE—INNOVATE
Zitieren
APA
Vlachostergios, P. J., Papathanassiou, M., Anagnostou, M., Thodou, E., Tamposis, I., Mitrakas, L., Zachos, I., Koukoulis, G. K., Samara, M., & Tzortzis, V. (2024). Mutational profile of primary clear cell renal cell carcinoma predicts recurrence and potential candidacy for adjuvant immune checkpoint inhibition. F1000Research. https://doi.org/10.12688/f1000research.136087.2
Vancouver
Vlachostergios PJ, Papathanassiou M, Anagnostou M, Thodou E, Tamposis I, Mitrakas L, et al. Mutational profile of primary clear cell renal cell carcinoma predicts recurrence and potential candidacy for adjuvant immune checkpoint inhibition. F1000Research. 2024. doi:10.12688/f1000research.136087.2
BibTeX
@article{Vlachostergios2024,
author = {Vlachostergios, Panagiotis J and Papathanassiou, Maria and Anagnostou, Maria and Thodou, Eleni and Tamposis, Ioannis and Mitrakas, Lampros and Zachos, Ioannis and Koukoulis, George K and Samara, Maria and Tzortzis, Vassilios},
title = {Mutational profile of primary clear cell renal cell carcinoma predicts recurrence and potential candidacy for adjuvant immune checkpoint inhibition},
journal = {F1000Research},
year = {2024},
doi = {10.12688/f1000research.136087.2}
}
EUVIMED